Can anti-TFPI drugs like HYMPAVZI reshape the standard of care in inhibitor-positive hemophilia?
Pfizer Inc. has moved a step closer to reshaping the treatment paradigm for one of hemophilia’s most challenging patient subgroups. The company’s investigational therapy HYMPAVZI (marstacimab) demonstrated a 93 percent reduction in bleeding episodes in patients with hemophilia A or B who have developed inhibitors, according to data presented at the 67th American Society of
